<?xml version='1.0' encoding='utf-8'?>
<document id="23860641"><sentence text="A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors."><entity charOffset="32-41" id="DDI-PubMed.23860641.s1.e0" text="RO4929097" /></sentence><sentence text="To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus"><entity charOffset="149-161" id="DDI-PubMed.23860641.s2.e0" text="temsirolimus" /></sentence><sentence text="" /><sentence text="Escalating doses of RO4929097 and temsirolimus were administered at three dose levels"><entity charOffset="20-29" id="DDI-PubMed.23860641.s4.e0" text="RO4929097" /><entity charOffset="34-46" id="DDI-PubMed.23860641.s4.e1" text="temsirolimus" /><pair ddi="false" e1="DDI-PubMed.23860641.s4.e0" e2="DDI-PubMed.23860641.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23860641.s4.e0" e2="DDI-PubMed.23860641.s4.e1" /></sentence><sentence text=" Patients received once daily oral RO4929097 on a 3 days on/4 days off schedule every week, and weekly intravenous temsirolimus"><entity charOffset="115-127" id="DDI-PubMed.23860641.s5.e0" text="temsirolimus" /></sentence><sentence text=" Blood samples were collected for PK analysis" /><sentence text=" Archival tissue specimens were collected for Notch pathway biomarker analysis and genotyping of frequent oncogenic mutations" /><sentence text="" /><sentence text="Seventeen patients with refractory advanced solid tumors were enrolled in three dose levels (DLs): DL1 (RO4929097 10 mg; Temsirolimus 25 mg), DL2 (RO4929097 20 mg; Temsirolimus 25 mg), and DL3 (RO4929097 20 mg; Temsirolimus 37"><entity charOffset="121-133" id="DDI-PubMed.23860641.s9.e0" text="Temsirolimus" /><entity charOffset="164-176" id="DDI-PubMed.23860641.s9.e1" text="Temsirolimus" /><entity charOffset="211-223" id="DDI-PubMed.23860641.s9.e2" text="Temsirolimus" /><pair ddi="false" e1="DDI-PubMed.23860641.s9.e0" e2="DDI-PubMed.23860641.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23860641.s9.e0" e2="DDI-PubMed.23860641.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23860641.s9.e0" e2="DDI-PubMed.23860641.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23860641.s9.e1" e2="DDI-PubMed.23860641.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23860641.s9.e1" e2="DDI-PubMed.23860641.s9.e2" /></sentence><sentence text="5 mg)" /><sentence text=" The most common toxicities related to the study drug combination included: fatigue (82 %; grade 3 6 %), mucositis, (71 %; grade 3 6 %), neutropenia (59 %; grade 3 12 %), anemia (59 %; grade 3 0 %), and hypertriglyceridemia (59 %; grade 3 0 %)" /><sentence text=" Two dose-limiting toxicities, grade 3 rash and grade 3 mucositis, were observed in the same patient in the first dose level prompting dose expansion" /><sentence text=" Eleven patients (73 %) had stable disease as their best response" /><sentence text=" Co-administration of RO4929097 was associated with increased clearance and reduced exposure to temsirolimus, suggestive of drug-drug interaction via CYP3A4 induction" /><sentence text=" No correlation between the expression of Notch pathway biomarkers or genotype and time to progression was noted" /><sentence text="" /><sentence text="RO4929097 can be safely combined with temsirolimus in patients with advanced solid tumors" /><sentence text=" The RP2D was established at 20 mg of RO4929097 combined with 37"><entity charOffset="38-47" id="DDI-PubMed.23860641.s18.e0" text="RO4929097" /></sentence><sentence text="5 mg of temsirolimus"><entity charOffset="8-20" id="DDI-PubMed.23860641.s19.e0" text="temsirolimus" /></sentence><sentence text="" /></document>